Core Viewpoint - The article highlights the significant trading activity in the ChiNext market, with a notable increase in turnover rates and the presence of institutional investors in several stocks, indicating potential investment opportunities and market interest [1][2][3]. Trading Performance - The ChiNext index rose by 1.50%, closing at 2345.37 points, with a total trading volume of 458.24 billion yuan, an increase of 9.49 billion yuan from the previous trading day [1]. - Among the 1114 tradable stocks, 1114 closed higher, with 17 stocks rising over 10%, including stocks like Copper Crown Copper Foil and Jin Chun Shares, which hit the daily limit [1]. - The average turnover rate for ChiNext stocks was 4.43%, with 40 stocks exceeding a turnover rate of 20% [1]. High Turnover Stocks - C Shanda, a newly listed stock, had the highest turnover rate at 55.61%, closing down by 9.07% with a trading volume of 1.18 billion yuan [1][2]. - Other high turnover stocks included Shen Nong Zhi Ye and Guan Long Energy, with turnover rates of 53.68% and 46.56%, respectively [1][2]. Institutional Activity - Nine stocks with high turnover rates appeared on the Dragon and Tiger list, indicating institutional trading activity [3]. - Shen Nong Zhi Ye and C Shanda saw significant net purchases from institutional investors, with net buys of 1.02 billion yuan and 1.21 billion yuan, respectively [3]. Fund Flow - Among high turnover stocks, 25 experienced net inflows from major funds, with Shen Nong Zhi Ye and Copper Crown Copper Foil leading with net inflows of 2.92 billion yuan and 2.15 billion yuan, respectively [4]. - Conversely, stocks like Jin Dun Shares and Zhen Dong Pharmaceutical faced significant net outflows, amounting to 88.59 million yuan and 65.90 million yuan, respectively [4]. Earnings Forecasts - Four high turnover stocks released earnings forecasts, all indicating profit increases, with Man Kun Technology expected to see a net profit increase of 66.81% [4].

Core Viewpoint - The article discusses the journey of Yao Xin, founder of PPLive, as he aims to establish a distributed computing network for the AI era through his new company, PPIO, which has recently filed for an IPO in Hong Kong [1][13]. Group 1: Company Background - Yao Xin founded PPLive in 2005 while studying at Huazhong University of Science and Technology, which later became a pioneer in China's internet video industry [1][3]. - PPLive reached 450 million users and raised over $700 million in funding before being sold to Suning for $420 million in 2014 [5][6]. - After a period of absence from the public eye, Yao Xin returned to entrepreneurship in 2018 by co-founding PPIO, focusing on addressing the market gap in computing power supply and demand [6][8]. Group 2: Business Model and Financials - PPIO aims to create a distributed cloud computing platform to overcome the limitations of traditional centralized cloud computing, particularly in meeting real-time inference needs [6][9]. - Projected revenues for PPIO from 2022 to 2024 are expected to grow from 286 million to 558 million RMB, with a compound annual growth rate (CAGR) of 39.7% [6][7]. - Despite revenue growth, PPIO has faced increasing net losses, projected to rise from 85 million to 294 million RMB over the same period, primarily due to high R&D expenses [6][7]. Group 3: Market Potential - The edge cloud market in China is projected to grow from 13.2 billion RMB in 2024 to 37 billion RMB by 2029, with a CAGR of 22.9%, while the global AI cloud computing market is expected to expand from 31.5 billion RMB to 427.7 billion RMB, reflecting a CAGR of 68.5% [8][9]. - PPIO's edge cloud services accounted for 98.1% of total revenue, with significant growth in edge CDN services, which increased from 9.5% to 28.1% of revenue over three years [9][11]. Group 4: Investment and Shareholder Structure - PPIO has completed five rounds of financing, with its valuation increasing from $46 million in the angel round to $469 million post-B round [11][13]. - The company has a strong shareholder base, including notable figures from the tech industry and leading venture capital firms, ensuring a solid governance structure post-IPO [11][13]. - Yao Xin and his wife hold a controlling stake of 50.61%, while co-founder Wang Wenyu owns 11.41% [11][13].

国投证券指出，创业板指为代表的低估值大盘成长板块在当前流动性充沛环境下正迎来估值修复机会。 创业板指PE为33.89倍，处于近十年23.82%分位，是主流宽基指数中估值水位最低的方向之一，同时其 Q1利润增速达19%，显著优于全A的3.46%。产业层面，AI算力、创新药、半导体、新能源等新动能行 业相继迎来周期性拐点，为创业板指占优提供支撑。当前市场正处于"新旧动能转换"第二阶段，科技科 创维持占优推荐，创业板指或成为最受益方向。 没有股票账户的投资者可关注国泰创业板50ETF发起联接A（023371），国泰创业板50ETF发起联接C （023372）。 注：如提及个股仅供参考，不代表投资建议。指数/基金短期涨跌幅及历史表现仅供分析参考，不预示 未来表现。市场观点随市场环境变化而变动，不构成任何投资建议或承诺。文中提及指数仅供参考，不 构成任何投资建议，也不构成对基金业绩的预测和保证。如需购买相关基金产品，请选择与风险等级相 匹配的产品。基金有风险，投资需谨慎。 （文章来源：每日经济新闻） 创业板50ETF国泰（159375）跟踪的是创业板50指数（399673），单日涨跌幅可达20%。该指数由深圳 证券交易 ...

中证1000收报6701.12点，涨1.42%。 深证成指收报11193.06点，涨1.21%。 创业板指收报2345.37点，涨1.50%。 沪深300收报4149.04点，涨0.71%。 科创50收报1032.84点，涨1.17%。 中证500收报6293.60点，涨1.56%。 上证指数收报3605.73点，涨0.65%。 ...

Market Overview - The A-share market saw all three major indices rise, with the Shanghai Composite Index increasing by 0.65%, the Shenzhen Component Index rising by 1.21%, and the ChiNext Index up by 1.5% [1] - The total trading volume in the Shanghai and Shenzhen markets reached 1.84 trillion yuan, a decrease of 19.9 billion yuan compared to the previous trading day [1] Stock Performance - Over 4,300 stocks in the market experienced gains, indicating a broad-based rally [1] - Sectors that performed well included Hainan Free Trade Zone, rare earth permanent magnets, duty-free shops, film and television, securities, and biopharmaceuticals [1] - Notable individual stock performances included: - Happiness Blue Ocean, Hainan Airport, and China Duty Free Group hitting the daily limit up - Tibet Summit rising over 7% - Huhua Co., Ltd. declining over 9% - Jiangnan Chemical falling over 5% - Zhongjin Gold dropping over 4% - Minsheng Bank decreasing over 2% [1]

| Hist | 公司简称 | 拟上板块 | 2024年扣非归母净 | | --- | --- | --- | --- | | | | | 润（亿元） | | 1 | 南网数字 | 创业板 | 5.62 | | 2 | 三瑞智能 | 创业板 | 3.21 | | 3 | 宏明电子 | 创业板 | 2.77 | | ব | 理奇智能 | 创业板 | 2.73 | | 5 | 麦田能源 | 创业板 | 2.22 | | 6 | 江松科技 | 创业板 | 1.87 | | 7 | 欣兴工具 | 创业板 | 1.84 | | 8 | 联亚药业 | 创业板 | 1.81 | | 9 | 固德电材 | 创业板 | 1.73 | | 10 | 欣强电子 | 创业板 | 1.68 | | 11 | 初源新材 | 创业板 | 1.50 | | 12 | 尚水智能 | 创业板 | 1.48 | | 13 | 慧谷新材 | 创业板 | 1.42 | | 14 | 金桥德克 | 创业板 | 1.35 | | 15 | 益丰新材 | 创业板 | 1.33 | | 16 | 艾为电气 | 创业板 | 1.02 | | 17 | 贝特利 ...

中国上证综指7月24日（周四）收盘上涨23.43点，涨幅：0.65%，报3605.73点； 中国深证成指7月24日（周四）收盘上涨134.02点，涨幅：1.21%，报11193.06点； 中国沪深300指数7月24日（周四）收盘上涨29.27点，涨幅：0.71%，报4149.04点； 中国创业板指数7月24日（周四）收盘上涨34.7点，涨幅：1.5%，报2345.37点； 中国科创50指数7月24日（周四）收盘上涨11.98点，涨幅：1.17%，报1032.84点。 ...

Group 1 - The current market environment favors the technology and innovation sectors, with the ChiNext Index representing a low valuation large-cap growth style that is expected to benefit significantly [1] - The ChiNext Index currently has a PE ratio of 33.89 times, which is at the 23.82% percentile over the past decade, indicating it is among the lowest valuation levels in mainstream broad-based indices [1] - New growth drivers such as AI (computing power), innovative pharmaceuticals, and new energy vehicles are experiencing cyclical turning points, providing fundamental support for the low valuation large-cap growth sector [1] Group 2 - The Sci-Tech Innovation and Entrepreneurship ETF (588360) tracks the Sci-Tech Innovation and Entrepreneurship 50 Index (931643), which can have daily fluctuations of up to 20% [1] - The index is compiled by China Securities Index Co., Ltd., selecting high-quality listed companies from the Sci-Tech Innovation Board and ChiNext market in fields such as new-generation information technology, biomedicine, and new materials [1] - The index focuses on technology companies with high growth characteristics, highlighting significant coverage of high-tech industries [1]

Group 1 - The overall market experienced a collective rise, with the pharmaceutical and biotechnology sector showing significant gains, particularly the vaccine ETF (159643) which increased by over 5% [1] - The National Healthcare Security Administration (NHSA) has initiated the 11th batch of centralized drug procurement, which includes 55 drug varieties across various therapeutic areas, such as chemical drugs and biosimilars [3] - The NHSA has established a clear principle of "no procurement for new drugs, procurement for non-new drugs," which delineates the boundary between old drug procurement and new drug protection, providing stable policy expectations for the innovative drug industry [3] Group 2 - It is projected that 2025 will be a pivotal year for the overseas expansion of Chinese innovative drugs, with numerous products expected to exceed peak sales of $3 billion to $5 billion, and record-breaking licensing transactions [4] - Domestic policy adjustments regarding the medical insurance catalog and the promotion of commercial insurance are seen as significant catalysts for investment opportunities in the innovative drug sector [4] - Chinese innovative drugs are recognized for their high efficiency and low-cost development advantages, particularly in competitive areas such as ADC, bispecific antibodies, and cell therapy, suggesting potential investment in innovative drug ETFs like Guotai (517110) [4]

Group 1 - The pharmaceutical and biotechnology industry is entering a dual-driven period of policy and technology, with the 2025 measures marking the transition to the 2.0 phase of China's innovative drug support policy, potentially activating a new round of opportunities in the innovative drug industry chain [1] - The reactivation of the fifth set of standards for the Sci-Tech Innovation Board and the complementary model of the Hong Kong Stock Exchange's 18A dual financing channel is expected to stimulate full-cycle financing for pharmaceutical companies [1] - In the medical device sector, the core trends are replacement and technology going abroad, with upgraded regulations for high-end medical devices driving innovation and industry breakthroughs [1] Group 2 - The domestic IVUS (Intravascular Ultrasound) and FFR (Fractional Flow Reserve) markets are maturing rapidly, with the IVUS market size projected to grow from 1.76 billion yuan in 2024 to 5.11 billion yuan by 2030, and the coronary direct measurement FFR market expected to expand from 230 million yuan in 2024 to 3.12 billion yuan by 2030 [1] - The demand for cardiovascular disease solutions is continuously increasing against the backdrop of an aging population, indicating significant industry potential [1] - The Guotai Pharmaceutical ETF (159377) tracks the innovative pharmaceutical index (399275), which can experience daily fluctuations of up to 20%, reflecting the overall performance of listed companies in the biopharmaceutical, medical device, and medical service sectors within the ChiNext market [1]